The effect of hydroxyurea on vasculopathy in a child with sickle cell disease

American Journal of Neuroradiology

Volumn 23, Issue 10, 2002, Pages 1692-1696

  Helton, Kathleen J ^a   Wang, Winfred C ^a   Wynn, Lynn W ^a   Khan, Raja B ^a   Steen, R Grant ^a  

^a Research Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; BRAIN ATROPHY; CASE REPORT; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; SCHOOL CHILD; SICKLE CELL ANEMIA;

ANTISICKLING AGENTS; BRAIN; CEREBROVASCULAR ACCIDENT; CHILD; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FETAL HEMOGLOBIN; HEMOGLOBIN SC DISEASE; HUMANS; HYDROXYUREA; MAGNETIC RESONANCE ANGIOGRAPHY; VASCULAR DISEASES; VASCULAR PATENCY;

EID: 0036846955     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle cell disease: A report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 1996;17:965- 972
2. Wang W, Langston J, Steen RG, et al. Abnormalities of the central nervous system in very young children with sickle cell anemia. J Pediatrics 1998;132:994-998
3. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998;91:288-294
4. Adams RJ, Nichols FT, McKie V, McKie K, Milner P, Gammal TE. Cerebral infarction in sickle cell anemia: Mechanism based on CT and MRI. Neurology 1988;38:1012-1017
5. Steen RG, Helton KJ, Horwitz EM, et al. Improved cerebrovascular patency following therapy in patients with sickle cell disease: Initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann Neurol 2001;49:222-229
6. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-1030
7. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999;94:3022-3026
8. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS Study, a phase I/II trial. Blood 1999;94:1550-1554
9. de Montalembert M, Davies SC. Is hydroxyurea leukemogenic in children with sickle cell disease? Blood 2001;98:2878-2879
10. Vichinsky EP, Lubin BH. A cautionary note regarding hydroxyurea in sickle cell disease. Blood 1994;83:1124-1128
11. Selby R, Nisbet-Brown E, Basran RK, Chang L, Olivieri NF. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood 1997;90:891-893
12. Russell MO, Goldberg HI, Reis L, et al. Transfusion therapy for cerebrovascular abnormalities in sickle cell disease. J Pediatr 1976;88:382-387
13. Russell MO, Goldberg HI, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 1984;63:162-169
14. Haacke EM, Lin W. Flow phenomena in magnetic resonance imaging: Basic concepts and technical developments. Neuroimaging Clin N Am 1992;2:623-637
15. Gillams AR, McMahon L, Weinberg G, Carter AP. MRA of the intracranial circulation in asymptomatic patients with sickle cell disease. Pediatr Radiol 1998;28:283-287
16. Bridges KR, Barabino GD, Brugnara C, et al. A multi-parameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996;88:4701-4710
17. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322
18. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Blood 1997;89:1078-1088